Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2013, Article ID 290734, 6 pages
Clinical Study

The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes

1Department of Endocrinology, Peking University Third Hospital, Beijing 100191, China
2Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing 100191, China

Received 30 March 2013; Revised 6 June 2013; Accepted 6 June 2013

Academic Editor: Ilias Migdalis

Copyright © 2013 Wen-hua Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aim. To investigate whether pioglitazone had detrimental effects on biochemical markers of bone turnover in patients with type 2 diabetes (T2DM). Methods. Seventy patients with T2DM were included in this study. The patients remained on their previous antihyperglycemic therapies during the trial. Pioglitazone was then added on their regimen for 3 months. Results. After 3 months of treatment with pioglitazone, the levels of fasting blood glucose and HbA1c were significantly decreased (  mmol/L versus  mmol/L and versus , resp., ), compared with baseline in the overall patients. Serum concentrations of P1NP and BAP were significantly decreased from baseline ( μg/L versus μg/L and μg/L versus μg/L, resp., ) in female group, but not in male group. The serum levels of OC and CTX were unchanged in both female and male subgroups. In addition, the levels of serum BAP and P1NP were significantly decreased after pioglitazone treatment in postmenopausal subgroup, comparing with baseline. Conclusion. Pioglitazone inhibits bone formation and does not seem to affect bone resorption. Postmenopausal female patients rather than premenopausal or male patients are particularly vulnerable to this side effect of pioglitazone.